Trend towards HTA collaboration boosts need for data
The rising popularity of health technology assessments (HTAs) and similar framework agreements is presenting new challenges for the pharmaceutical industry.…
Healthcare Reform
-
-
Germany’s ESG Law: A case study for new pharma pricing model
Pharmaceutical pricing is increasingly becoming a broader topic in the global push towards sustainability and environmental, social, and government (ESG)…
-
AMNOG ten years on: Impact on the Europe top 5 price level hierarchy
Ten years after implementation of the AMNOG reform in Germany, the price level hierarchy among the Europe Top 5 markets…
-
US drug prices rise over 4% in 2021 reversing multi-year trend of slowed growth
Usually in January, every year, a large number of pharmaceutical companies update product prices - a trend that often receives…
-
Pharma and healthcare top 10: What to expect in 2021 and beyond
After the extreme unpredictability of 2020, the world is now looking at 2021 with the hope to return to a…
-
Risks to UK pharmaceutical spending from a US-UK free trade deal
A leaked document about UK-US free trade deal discussions back in 2017 has dominated UK media coverage over the past…
-
Germany’s fixed pricing for medicines faces European reckoning
Fixed prices for prescription medicines are an important part of the framework of pharmaceutical pricing and reimbursement regulation in Germany.…
-
Ten-year Medicare budget impact of increased coverage for anti-obesity intervention
Obesity rates have reached 37.5% and 39.4% among men and women age 60 and older by 2014, respectively, compared to…
-
South Korean pharma dreams struggle
In September, South Korean drugmaker Hanmi Pharmaceutical signed a collaboration agreement with US biotech Phanes Therapeutics focusing on dual- and…
-
Taking the pulse of international reference pricing
What a difference a year (or two) makes. When we published the 2017 edition of our International Reference Pricing Guidebook,…
